A Phase 1 study of BGB-43395 in advanced solid tumors

Recruiting Phase 1 NCT06120283

Study Description

A study to evaluate the safety and effectiveness of the investigational drug BGB-43395, alone or in combination with other therapies, in patients with advanced breast cancer and other solid tumors

Study Details

Registry ID:
NCT06120283
Conditions:
Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer
Phase:
Phase 1
Target Enrollment:
399 participants
Start Date:
Healthy Volunteers:
No

Study Locations (80 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →